Merck (MRK) Liabilities and Shareholders Equity (2009 - 2026)

Merck (MRK) has 18 years of Liabilities and Shareholders Equity data on file, last reported at $128.7 billion in Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 11.78% year-over-year to $128.7 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $512.6 billion (up 10.86% YoY) and the FY2025 annual result came in at $136.9 billion, up 16.87% from the prior year.
• Liabilities and Shareholders Equity declined to $128.7 billion in Q1 2026 per MRK's latest filing, from $136.9 billion in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $136.9 billion in Q4 2025 and bottomed at $104.5 billion in Q2 2023.
• The 5-year median for Liabilities and Shareholders Equity is $109.2 billion (2022), against an average of $113.9 billion.
• The widest annual swing landed in 2022, when Liabilities and Shareholders Equity rose 18.09%; it then declined 2.45% in 2023.
• Tracing MRK's Liabilities and Shareholders Equity over 5 years: stood at $109.2 billion in 2022, then declined by 2.28% to $106.7 billion in 2023, then increased by 9.78% to $117.1 billion in 2024, then increased by 16.87% to $136.9 billion in 2025, then fell by 5.98% to $128.7 billion in 2026.
• Per Business Quant, the three latest MRK Liabilities and Shareholders Equity figures stand at $128.7 billion (Q1 2026), $136.9 billion (Q4 2025), and $129.5 billion (Q3 2025).

Peer Comparison